Nivolumab plus gemcitabine–cisplatin for unresectable or metastatic urothelial carcinoma: health-related quality-of-life analyses from the phase III CheckMate 901 trial
Adding nivolumab to gemcitabine-cisplatin did not worsen HRQoL compared with gemcitabine-cisplatin alone in the first 16 weeks of therapy. These findings support nivolumab plus gemcitabine-cisplatin as standard first-line therapy for cisplatin-eligible patients with unresectable or metastatic UC.
Authors
- S.I. Blum
- M.S. van der Heijden
- G. Sonpavde
- L. Shi
- T. Powles
- W. Liao
- J. Bedke
- S. Mitra
- M.D. Galsky
- M.Y. Patel
Institutions
- Ithaka Harbors (US)
- Harvard University (US)
- Queen Mary University of London (GB)
- The Netherlands Cancer Institute (NL)
- Bristol-Myers Squibb (United States) (US)
- Oncode Institute (NL)
- Dana-Farber Cancer Institute (US)
- University of Tübingen (DE)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106089
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- University of Pittsburgh
- Ono Pharmaceutical